Shifting from clinician-ordered to pathologist-initiated reflex testing for NSCLC biomarkers combines diagnosis and molecular analysis into one workflow. This operational change minimizes delays, increases testing rates, and optimizes the use of small biopsy samples, getting actionable results to oncologists faster.

In urgent clinical scenarios with very sick patients, chemotherapy remains the core initial treatment. Targeted or immunotherapies can be added later once results for key biomarkers like MSI, HER2, PD-L1, and CLDN18.2 are available. This prioritizes immediate patient stability over a delayed precision approach.

To reduce treatment delays, pathologists should initiate biomarker testing reflexively. Waiting for a medical oncologist to order tests at a first visit is a system failure, wasting critical time and risking the need to retrieve archived samples.

Despite promising trial data for Tarlatumab in first-line small cell lung cancer, its clear survival benefit as a second-line therapy makes clinicians reluctant to lose it as a reliable later-stage option. This creates a strategic dilemma about the optimal timing to deploy the most effective new therapies.

The aggressive nature of small cell lung cancer (SCLC) demands immediate treatment, often within days. This urgency, while necessary for disease control, paradoxically restricts patients' ability to seek second opinions, process their diagnosis, or enroll in first-line clinical trials, which providers may bypass for faster standard care.

When a lung cancer patient is too symptomatic to wait for genomic testing results, the expert consensus is to initiate treatment with chemotherapy alone. Adding immunotherapy upfront is ill-advised, as its use in EGFR-mutated patients (a common finding) can be detrimental.

Because POLE testing often requires a send-out NGS test, the turnaround time is slow. Clinicians report they cannot wait for these results and must make treatment decisions, such as starting chemotherapy for a p53-mutant tumor, before the full molecular profile, including the crucial POLE status, is known.

Unlike rare biomarkers that necessitate a 'test-and-wait' approach, IB6 is expressed in over 80-90% of NSCLC tumors. This ubiquity could make pre-screening unnecessary for drugs like Sigvotatug Vedotin, allowing clinicians to initiate targeted therapy much faster and for a broader patient population.

Data shows an average two-week delay occurs between a lung cancer patient's biopsy and the ordering of essential biomarker tests. This administrative gap, separate from the diagnostic process itself, is a major bottleneck that postpones critical treatment decisions.